Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...
Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. TURKU, FI / ...
Socioeconomic and demographic factors impact surgical outcomes in upper extremity soft tissue sarcomas, affecting amputation ...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today ...
The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...
Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...
Prognostic factors in soft tissue sarcomas encompass a diverse spectrum of clinical, pathological and host-related parameters that influence patient outcomes. Increasingly, research is demonstrating ...
What at least one investigator has been saying for nearly 2 decades is supported by a new study: 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) can provide important prognostic ...
A recent analysis reveals that the incidence rates of soft tissue sarcomas—cancers in muscle, fat, blood vessels, nerves, and tendons—are lower in young U.S. active-duty military servicemen compared ...
Soft tissue sarcomas (STS) represent a heterogeneous group of extraskeletal mesenchymal tumors that affect individuals throughout the entire age continuum. Despite this pervasive influence, key ...
Canine soft tissue sarcomas (STS) constitute a heterogeneous group of mesenchymal tumours that present diverse morphological and clinical profiles. These neoplasms commonly affect the skin and ...
Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. TURKU, FI / A ...